These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

186 related articles for article (PubMed ID: 38345160)

  • 21. Panobinostat treatment depletes EZH2 and DNMT1 levels and enhances decitabine mediated de-repression of JunB and loss of survival of human acute leukemia cells.
    Fiskus W; Buckley K; Rao R; Mandawat A; Yang Y; Joshi R; Wang Y; Balusu R; Chen J; Koul S; Joshi A; Upadhyay S; Atadja P; Bhalla KN
    Cancer Biol Ther; 2009 May; 8(10):939-50. PubMed ID: 19279403
    [TBL] [Abstract][Full Text] [Related]  

  • 22. Oral Azacitidine (CC-486) for the Treatment of Myeloid Malignancies.
    Garcia-Manero G; Döhner H; Wei AH; La Torre I; Skikne B; Beach CL; Santini V
    Clin Lymphoma Myeloma Leuk; 2022 Apr; 22(4):236-250. PubMed ID: 34758945
    [TBL] [Abstract][Full Text] [Related]  

  • 23. Comparison of Azacitidine and Decitabine in Myelodysplastic Syndromes and Acute Myeloid Leukemia: A Network Meta-analysis.
    Liu W; Zhou Z; Chen L; Wang X
    Clin Lymphoma Myeloma Leuk; 2021 Jun; 21(6):e530-e544. PubMed ID: 33716056
    [TBL] [Abstract][Full Text] [Related]  

  • 24. Maintenance Therapy with Decitabine after Allogeneic Stem Cell Transplantation for Acute Myelogenous Leukemia and Myelodysplastic Syndrome.
    Pusic I; Choi J; Fiala MA; Gao F; Holt M; Cashen AF; Vij R; Abboud CN; Stockerl-Goldstein KE; Jacoby MA; Uy GL; Westervelt P; DiPersio JF
    Biol Blood Marrow Transplant; 2015 Oct; 21(10):1761-9. PubMed ID: 26055299
    [TBL] [Abstract][Full Text] [Related]  

  • 25. Extended experience with a non-cytotoxic DNMT1-targeting regimen of decitabine to treat myeloid malignancies.
    Awada H; Mahfouz RZ; Kishtagari A; Kuzmanovic T; Durrani J; Kerr CM; Patel BJ; Visconte V; Radivoyevitch T; Lichtin A; Carraway HE; Maciejewski JP; Saunthararajah Y
    Br J Haematol; 2020 Mar; 188(6):924-929. PubMed ID: 31736067
    [TBL] [Abstract][Full Text] [Related]  

  • 26. Targeting epigenetic pathways in acute myeloid leukemia and myelodysplastic syndrome: a systematic review of hypomethylating agents trials.
    Yun S; Vincelette ND; Abraham I; Robertson KD; Fernandez-Zapico ME; Patnaik MM
    Clin Epigenetics; 2016; 8():68. PubMed ID: 27307795
    [TBL] [Abstract][Full Text] [Related]  

  • 27. DNA methyltransferase-1 in acute myeloid leukaemia: beyond the maintenance of DNA methylation.
    Li M; Zhang D
    Ann Med; 2022 Dec; 54(1):2011-2023. PubMed ID: 35838271
    [TBL] [Abstract][Full Text] [Related]  

  • 28. Clonal selection in therapy-related myelodysplastic syndromes and acute myeloid leukemia under azacitidine treatment.
    Calleja A; Yun S; Moreilhon C; Karsenti JM; Gastaud L; Mannone L; Komrokji R; Al Ali N; Dadone-Montaudie B; Robert G; Auberger P; Raynaud S; Sallman DA; Cluzeau T
    Eur J Haematol; 2020 May; 104(5):488-498. PubMed ID: 31990086
    [TBL] [Abstract][Full Text] [Related]  

  • 29. MUC1-C induces DNA methyltransferase 1 and represses tumor suppressor genes in acute myeloid leukemia.
    Tagde A; Rajabi H; Stroopinsky D; Gali R; Alam M; Bouillez A; Kharbanda S; Stone R; Avigan D; Kufe D
    Oncotarget; 2016 Jun; 7(26):38974-38987. PubMed ID: 27259275
    [TBL] [Abstract][Full Text] [Related]  

  • 30. Hypomethylating agents for the treatment of myelodysplastic syndromes and acute myeloid leukemia: Past discoveries and future directions.
    Short NJ; Kantarjian H
    Am J Hematol; 2022 Dec; 97(12):1616-1626. PubMed ID: 35871436
    [TBL] [Abstract][Full Text] [Related]  

  • 31. Clinical update on hypomethylating agents.
    Duchmann M; Itzykson R
    Int J Hematol; 2019 Aug; 110(2):161-169. PubMed ID: 31020568
    [TBL] [Abstract][Full Text] [Related]  

  • 32. DNA Methylation-Based Epigenetic Repression of SLC22A4 Promotes Resistance to Cytarabine in Acute Myeloid Leukemia.
    Buelow DR; Anderson JT; Pounds SB; Shi L; Lamba JK; Hu S; Gibson AA; Goodwin EA; Sparreboom A; Baker SD
    Clin Transl Sci; 2021 Jan; 14(1):137-142. PubMed ID: 32905646
    [TBL] [Abstract][Full Text] [Related]  

  • 33. Epigenetic Anti-Cancer Treatment With a Stabilized Carbocyclic Decitabine Analogue.
    Traube FR; Brás NF; Roos WP; Sommermann CC; Diehl T; Mayer RJ; Ofial AR; Müller M; Zipse H; Carell T
    Chemistry; 2022 May; 28(26):e202200640. PubMed ID: 35285586
    [TBL] [Abstract][Full Text] [Related]  

  • 34. One plus one does not always equal two, especially with regard to hypomethylating agents: the question of synergy of azacitidine and lenalidomide for treatment of relapsed acute myeloid leukemia and myelodysplastic syndromes post allogeneic hematopoietic stem cell transplant.
    Bewersdorf JP; Stahl M; Zeidan AM
    Expert Rev Hematol; 2019 Aug; 12(8):575-578. PubMed ID: 31225770
    [TBL] [Abstract][Full Text] [Related]  

  • 35. Epigenetic therapy: Research progress of decitabine in the treatment of solid tumors.
    Ye C; Jiang N; Zheng J; Zhang S; Zhang J; Zhou J
    Biochim Biophys Acta Rev Cancer; 2024 Mar; 1879(2):189066. PubMed ID: 38163523
    [TBL] [Abstract][Full Text] [Related]  

  • 36. Safety and preliminary efficacy of venetoclax with decitabine or azacitidine in elderly patients with previously untreated acute myeloid leukaemia: a non-randomised, open-label, phase 1b study.
    DiNardo CD; Pratz KW; Letai A; Jonas BA; Wei AH; Thirman M; Arellano M; Frattini MG; Kantarjian H; Popovic R; Chyla B; Xu T; Dunbar M; Agarwal SK; Humerickhouse R; Mabry M; Potluri J; Konopleva M; Pollyea DA
    Lancet Oncol; 2018 Feb; 19(2):216-228. PubMed ID: 29339097
    [TBL] [Abstract][Full Text] [Related]  

  • 37. Discovery of a first-in-class reversible DNMT1-selective inhibitor with improved tolerability and efficacy in acute myeloid leukemia.
    Pappalardi MB; Keenan K; Cockerill M; Kellner WA; Stowell A; Sherk C; Wong K; Pathuri S; Briand J; Steidel M; Chapman P; Groy A; Wiseman AK; McHugh CF; Campobasso N; Graves AP; Fairweather E; Werner T; Raoof A; Butlin RJ; Rueda L; Horton JR; Fosbenner DT; Zhang C; Handler JL; Muliaditan M; Mebrahtu M; Jaworski JP; McNulty DE; Burt C; Eberl HC; Taylor AN; Ho T; Merrihew S; Foley SW; Rutkowska A; Li M; Romeril SP; Goldberg K; Zhang X; Kershaw CS; Bantscheff M; Jurewicz AJ; Minthorn E; Grandi P; Patel M; Benowitz AB; Mohammad HP; Gilmartin AG; Prinjha RK; Ogilvie D; Carpenter C; Heerding D; Baylin SB; Jones PA; Cheng X; King BW; Luengo JI; Jordan AM; Waddell I; Kruger RG; McCabe MT
    Nat Cancer; 2021 Oct; 2(10):1002-1017. PubMed ID: 34790902
    [TBL] [Abstract][Full Text] [Related]  

  • 38. Decitabine has a biphasic effect on natural killer cell viability, phenotype, and function under proliferative conditions.
    Kopp LM; Ray A; Denman CJ; Senyukov VS; Somanchi SS; Zhu S; Lee DA
    Mol Immunol; 2013 Jul; 54(3-4):296-301. PubMed ID: 23328088
    [TBL] [Abstract][Full Text] [Related]  

  • 39. Clinical status of induction therapy incorporating a hypomethylating agent for newly diagnosed adult acute myeloid leukemia compared to the standard 7+3 regimen.
    Ohmoto A; Fuji S
    Expert Rev Hematol; 2023; 16(10):761-771. PubMed ID: 37670667
    [TBL] [Abstract][Full Text] [Related]  

  • 40. Digging deep into "dirty" drugs - modulation of the methylation machinery.
    Pleyer L; Greil R
    Drug Metab Rev; 2015 May; 47(2):252-79. PubMed ID: 25566693
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 10.